References
- Hauser WA, Hesdorffer DC. Epilepsy' frequency, causes and consequences. Demos, New York, USA (1990).
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl. I Med. 342(5), 314–319 (2000). Critical paper in outlining the ability to identify drug resistance early in the course of epilepsy.
- Beghi E, Di Mascio R, Tognoni, G. Drug treatment of epilepsy. outlines, criticism and perspectives. DITIF 31,249–265 (1986).
- Dlugos DJ eta Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology57(12), 2259–2264 (2001).
- Semah, F, Picot MC, Adam C etal Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neumlogy 51(5), 1256–1262 (1998).
- Berg At et al Early development of intractable epilepsy in children. A prospective study. Neurology 56(11), 1445–1452 (2001).
- Mattson RII et al Prognosis for total control of complex partial and secondary generalized tonic-clonic seizures. Neumlogy 47,68–76 (1996).
- Annegers JF et al Risk of recurrence after an initial unprovoked seizure. Epilepsia 27(1), 43–50 (1986).
- Berg AT eta]. Predictors of intractable epilepsy in childhood: a case-control study. Epilepsia 37,24–30 (1996).
- Huttenlocher P. When does childhood epilepsy become intractable? Indications and contraindications for epilepsy surgery in children. Seminars Pediatric Neurology 1, 118–126 (1994).
- Stephen LJ et al. Does the cause of localization-related epilepsy influence the response to anti-epileptic drug treatment? Epilepsia 42 (3), 357–362 (2001).
- French JA eta Characteristics of mesial temporal lobe epilepsy: results of history and physical examination. Ann. Neural 34, 774–780 (1993).
- Brodie MJ, Kwan P Staged approach to epilepsy management. Neurology 58, s2–8 (2002).
- Camfield C eta]. Does the number of seizures before treatment influence ease of control or remission of childhood epilepsy? Not if the number is 10 or less. Neurology 46(1), 41–44 (1996).
- Beghi E eta]. Prognosis of epilepsy in newly referred patients: a multicenter prospective study. Epilepsia 29(3), 236–243 (1988).
- Watts AE. The natural history of untreated epilepsy in a rural community in Africa. Epilepsia 33,464–468 (1992).
- Scheffer IE, Bhatia KP, Lopes-Cendes I etal. Autosomal dominant nocturnal frontal lobe epilepsy: A distinctive clinical disorder. Brain 118,61–73 (1995).
- Oldani A, Zucconi M, Asselta R eta]. Autosomal dominant nocturnal frontal lobe epilepsy: A video-polysomnographic and genetic appraisal of 40 patients and delineation of the epileptic syndrome. Brain 121,205–223 (1998).
- Ortells MO, Barrantes GE. Molecular modeling of the interactions of carbamazepine and a nicotinic receptor involved in the autosomal dominant nocturnal frontal lobe epilepsy. Br J.Pharmacol. 136(6), 883–895 (2002).
- Sisodiya SM eta Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125(1), 22–31 (2002).
- •Nice discussion of the role of drug resistance proteins in epilepsy.
- Dombrowski SM et al Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42(12), 1501–1506 (2001).
- Sisodiya SM eta Multi-drug resistdrug resistance protein 1 in focal cortical dysplasias. Lancet 357,42–43 (2001).
- Tishler DM etal MDR1gene expression in brain of patients with medically intractable epilepsy. Epiltpsia36(1), 1–6 (1995).
- Evans WE eta]. Pharmacogenenomics: translating functional genomics into rational therapeutics. Science 286(5439), 487–491 (1999).
- •Excellent overview of the field of pharmacogenetics
- Loscher W, Reissmuller E, Ebert U. Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats. Epilepsy Res. 40(1), 63–77 (2000).